Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ompenaclid in Advanced Gastrointestinal Malignancies
NCT03597581Phase 1Completed
- Sponsor
- Inspirna
- Start
- Jun 2018
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ompenaclid in colorectal cancer (CRC) and gastrointestinal cancer, sponsored by Inspirna. Primary endpoints: Maximum Tolerated Dose at 6 months, Overall Response Rate at 24 months and 1 more. Started Jun 2018; status: completed.
02
Drugs
ompenaclid
03
Conditions
colorectal cancer (CRC)gastrointestinal cancer
Beyond the preview
Go deeper on NCT03597581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03597581.